Two new indications approved for Cosentyx

The licensed indications for Cosentyx (secukinumab) have been extended to include the treatment of active psoriatic arthritis in patients with an inadequate response to DMARD therapy and the treatment of active ankylosing spondylitis in patients with an inadequate response to conventional therapy.

The interleukin-17A-targeting antibody is licensed for use as monotherapy in both indications and in psoriatic arthritis may also be used in combination with methotrexate.

Cosentyx remains licensed for use in the treatment of moderate to severe plaque psoriasis.